Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUSNYSE:BHCNASDAQ:BLTENASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsBHCBausch Health Cos$6.44+0.4%$5.14$3.96▼$9.85$2.38B0.282.62 million shs2.70 million shsBLTEBelite Bio$59.04-1.4%$61.69$43.70▼$86.53$1.88B-1.4445,303 shs31,499 shsLGNDLigand Pharmaceuticals$114.15-1.3%$107.71$81.74▼$129.90$2.20B0.83118,164 shs327,870 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos0.00%+4.29%+42.05%-0.77%-7.68%BLTEBelite Bio0.00%-2.38%-9.86%-10.84%+29.25%LGNDLigand Pharmaceuticals0.00%+0.07%+10.64%+8.57%+35.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos3.8295 of 5 stars1.93.00.04.03.23.30.6BLTEBelite Bio2.5828 of 5 stars3.52.00.00.03.80.80.6LGNDLigand Pharmaceuticals4.7331 of 5 stars3.53.00.04.42.23.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUSAkouos 0.00N/AN/AN/ABHCBausch Health Cos 1.86Reduce$7.4215.26% UpsideBLTEBelite Bio 3.00Buy$96.6763.73% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1428.03% UpsideCurrent Analyst Ratings BreakdownLatest AKUS, LGND, BHC, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/2/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/7/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.50(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUSAkouosN/AN/AN/AN/A$4.90 per shareN/ABHCBausch Health Cos$9.63B0.25$7.75 per share0.83($0.89) per share-7.23BLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/ALGNDLigand Pharmaceuticals$167.13M13.18$1.61 per share71.04$43.95 per share2.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/ABHCBausch Health Cos-$46M-$0.11N/A1.38N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)BLTEBelite Bio-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A30.77N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)Latest AKUS, LGND, BHC, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUSAkouosN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUSAkouosN/A17.3017.30BHCBausch Health CosN/A1.350.97BLTEBelite BioN/A24.3124.31LGNDLigand PharmaceuticalsN/A5.275.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUSAkouosN/ABHCBausch Health Cos78.65%BLTEBelite Bio0.53%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipAKUSAkouos4.80%BHCBausch Health Cos8.12%BLTEBelite Bio13.29%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableBHCBausch Health Cos20,700370.08 million340.03 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableAKUS, LGND, BHC, and BLTE HeadlinesRecent News About These CompaniesLisanti Capital Growth LLC Acquires 13,565 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 29 at 6:33 AM | marketbeat.comLGND Ligand Pharmaceuticals Incorporated - Seeking AlphaJune 26, 2025 | seekingalpha.comAndrew Reardon Sells 500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 26, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,040.00 in StockJune 25, 2025 | marketbeat.comLigand Pharmaceuticals: Attractive Royalty Model Powers ForwardJune 24, 2025 | seekingalpha.comAdvisor Resource Council Makes New $2.24 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 21, 2025 | marketbeat.comSG Americas Securities LLC Acquires 5,201 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 21, 2025 | marketbeat.comChicago Capital LLC Has $58.30 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 17, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 16, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,270.00 in StockJune 13, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 500 SharesJune 12, 2025 | marketbeat.comLGND Makes Bullish Cross Above Critical Moving AverageJune 11, 2025 | nasdaq.comLigand Announces 2025 Investor Day in New York CityJune 11, 2025 | globenewswire.comGAMMA Investing LLC Purchases 61,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 10, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from BrokeragesJune 10, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Congress Asset Management Co.June 7, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 1,000 SharesJune 3, 2025 | marketbeat.comAndrew Reardon Sells 1,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 3, 2025 | insidertrades.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.40 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 3, 2025 | marketbeat.comSummit Global Investments Acquires 6,407 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 1, 2025 | marketbeat.comKings Path Partners LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKUS, LGND, BHC, and BLTE Company DescriptionsAkouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Bausch Health Cos NYSE:BHC$6.44 +0.03 (+0.39%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$6.51 +0.07 (+1.15%) As of 06/27/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Belite Bio NASDAQ:BLTE$59.04 -0.86 (-1.44%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$58.42 -0.62 (-1.04%) As of 06/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Ligand Pharmaceuticals NASDAQ:LGND$114.15 -1.54 (-1.33%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$114.10 -0.06 (-0.05%) As of 06/27/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
